Advertisement
News
Advertisement

Invited by Ontario's Ministry of Economic Development and Innovation and the Canadian Trade Commissioner Service, these meeting provided an opportunity for potential collaboration ...

Thu, 03/08/2012 - 8:45am
The Associated Press

(http://www.CardioComm.com)

CardioComm Solutions, Inc. (CardioComm Solutions) (TSX VENTURE: EKG)

was identified as a company of interest to participate in a one day

exchange (March 7, 2012) of information and ideas with a visiting

Japanese medical technology delegation sponsored by the Ontario's

Ministry of Economic Development and Innovation, in partnership with

the Canadian Trade Commissioner Service. The objectives of the mission

were to promote partnership in innovation, R&D, trade and investment

in the area of medical imaging between Canada and Japan.

The one-on-one meetings between CardioComm Solutions and the visiting

Japanese companies explored areas of collaboration which could lead to

new commercialization opportunities for CardioComm Solutions'

bio-monitoring technologies. Given the confidential nature of the

meetings and to respect the wishes of the delegation and the Canadian

Trade Commissioner Service, the participating organizations from the

Japanese delegation will not be disclosed at this date.

CardioComm Solutions is a medical software engineering company

specializing in the management of electrocardiograms ("EKGs"), one of

the most common diagnostic tests performed. Over the past three years

the company has successfully launched solutions that enable the

receipt, review and interpretation of EKGs through the use of newer

medical devices and communication portals over internet and cellular

based technologies. Their EKG management solutions can now service

both medical and consumer markets internationally. "Our Global EKG

Management System (GEMS) is comprised of two technologies. The first

enables the capture and importation of EKG recordings from FDA cleared

devices such as the HeartCheck PEN, Mobile Cardiac Telemetry Devices

("MCT"), 12 lead EKG machines and cardiac event loop recorders

("ELRS"). Our second proprietary technology is an EKG "viewer" that

forms the core of our family of products allowing the EKG wave form to

be acquired, reviewed, interpreted and saved, thereby enabling medical

professionals to make diagnoses for cardiac arrhythmias. Our EKG SDK

viewer is a technology of specific interest to our larger clients as

it can be integrated to their own proprietary workflow systems without

GEMS," said Etienne Grima, CEO of CardioComm Solutions.

"Discussions with the visiting delegates highlighted the importance of

having access to ready-to-market and proven medical solutions. The

Japanese market is active in searching out technologies such as ours

to service their growing In-Hospital, Point of Care and Home

Monitoring needs. With over 200 million citizens, the consumer market

importance also cannot be understated. Follow up discussions are

planned as well as the potential for a CardioComm Solutions visit to

Japan in 2012," added Grima.

"We were very pleased to have been asked to attend the closed door

meetings and to learn more about Japanese advanced technologies. The

meetings also allowed us to share our plans for leveraging our history

of performance in the health care market as we take first steps

towards integrating with new consumer EKG and other bio-sign

monitoring devices under the GEMSTM 4.0 software platform. This event

presented an excellent opportunity for access into the Japanese

market, a medical device market worth approximately $32 billion," said

Simi Grosman, member of the board of directors for CardioComm

Solutions.

About CardioComm Solutions

CardioComm Solution's patented and proprietary technology is used in

products for recording, viewing, analyzing and storing

electrocardiograms for diagnosis and management of cardiac patients.

CardioComm Solutions also is cleared by the FDA for the sales of a

consumer based HeartCheck PEN handheld EKG device and home version of

its proprietary GEMS Home software. Products are sold worldwide

through a combination of an external distribution network and a North

American-based sales team. The company has earned the ISO 13485

certification, is HPB approved, HIPAA compliant, and has received FDA

market clearance for its software devices. CardioComm Solutions, Inc.

is headquartered in Toronto, Canada, with offices in Victoria, B.C.

Forward-looking statements

This release may contain certain forward-looking statements with

respect to the financial condition, results of operations and business

of CardioComm Solutions and certain of the plans and objectives of

CardioComm Solutions with respect to these items. By their nature,

forward-looking statements involve risk and uncertainty because they

relate to events and depend on circumstances that will occur in the

future and there are many factors that could cause actual results and

developments to differ materially from those expressed or implied by

these forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as

that term is defined in policies of the TSX Venture Exchange) accepts

responsibility for the adequacy or accuracy of this release.

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading